Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
June 2024
Combination of anti-SSA/Ro60 and anti-dsDNA serotype is predictive of belimumab renal response in patients with lupus nephritis
Lupus Sci Med. 2024 May 28;11(1) doi: 10.1136/lupus-2024-001156
The combination of anti-dsDNA and anti-SSA/Ro60 serotype may help to foretell the patient’s renal response to belimumab. Investigators here aimed to explore the effectiveness of belimumab on active LN, exploring predictors, including serological biomarkers, of renal response to belimumab in a real-world setting.
Keywords:
Efficacy and safety of telitacicept therapy in systemic lupus erythematosus with hematological involvement
Clin Rheumatol. 2024 May 20 doi: 10.1007/s10067-024-06992-7. Epub ahead of print
This real-world combination of telitacicept and standard treatment demonstrated significant improvements in anaemia, as well as increased leukocyte and platelet levels in patients with SLE and haematological involvement. Here, investigators sought to evaluate the efficacy and safety of telitacicept in combination with standard treatment in SLE patients specifically with haematological involvement.
Keywords:
January 2024
Burden of Systemic Lupus Erythematosus in Clinical Practice: Baseline Data from the SLE Prospective Observational Cohort Study (SPOCS) by Interferon Gene Signature
Lupus Sci Med. 2023; 10(2):e001032 DOI: 10.1136/lupus-2023-001032
This study from Arnaud et al described baseline characteristics of SLE patients grouped by disease activity and IFNGS category in the international SPOCS study. IFNGS-high patients were younger at SLE diagnosis, and a baseline SLEDAI-2K score ≥10 was associated with shorter disease duration, more frequent and more severe flares. IFNGS-low patients were more likely to exhibit musculoskeletal and CNS comorbidities than IFNGS-high patients. Continuation of the SPOCS study will allow investigation into how different baseline characteristics affect long-term outcomes in SLE patients.
Keywords:
December 2023
Efficacy and Safety of Telitacicept in Patients with Systemic Lupus Erythematosus: A Multicentre, Retrospective, Real-World Study
Lupus Sci. Med. 2023;10(2):e001074 DOI 10.1136/lupus-2023-001074
In this study, telitacicept add-on therapy demonstrated desirable real-world safety and efficacy profiles for the management of SLE, LN, and patients with haematological abnormalities.
August 2023
SGLT2 Inhibitors Alleviated Podocyte Damage in Lupus Nephritis by Decreasing Inflammation and Enhancing Autophagy
Ann Rheum Dis. 2023 DOI: 10.1136/ard-2023-224242
Data revealed a renoprotective effect of SGLT2 inhibitors by reducing proteinuria and preserving renal function in the murine MRL/lpr lupus model.
May 2022
Impact of belimumab on organ damage in systemic lupus erythematosus
Arthritis Care Res (Hoboken). 2022 Epub ahead of print doi: 10.1002/acr.24901
Review of clinical trial and real-world data on the effects of belimumab on organ damage in adult patients with SLE shows that belimumab reduces key drivers of organ damage, decreases organ damage progression and, in those with lupus nephritis (LN), decreases renal-related events.
Keywords:
February 2022
Real-world Impact of Flaring on Patient-Reported Outcomes and Healthcare Resource Utilisation in Systemic Lupus Erythematosus
Clin Exp Rheumatol. 2021.Epub ahead of print
Data from the real world underscores the need for more effective strategies and treatments to alleviate or prevent flaring in systemic lupus erythematosus (SLE).
Despite data from Hong Kong and Canada showing an association of flaring with reduced health-related quality of life and increased healthcare resourse utilisation and costs, similar international data are limited.